[go: up one dir, main page]

NO20081862L - Alkylsulfoksidkinoliner som NK-3-reseptorligander - Google Patents

Alkylsulfoksidkinoliner som NK-3-reseptorligander

Info

Publication number
NO20081862L
NO20081862L NO20081862A NO20081862A NO20081862L NO 20081862 L NO20081862 L NO 20081862L NO 20081862 A NO20081862 A NO 20081862A NO 20081862 A NO20081862 A NO 20081862A NO 20081862 L NO20081862 L NO 20081862L
Authority
NO
Norway
Prior art keywords
alkylsulfoxide
quinolines
receptor ligands
compounds
processes
Prior art date
Application number
NO20081862A
Other languages
English (en)
Inventor
James Kang
Cristobal Alhambra
Yan Li
Thomas R Simpson
Jeffrey S Albert
Gerard M Koether
James Woods
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37889114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081862(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20081862L publication Critical patent/NO20081862L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser med formel (I) hvori R1, A, R2, R3, R4, R5, n, m og q er som beskrevet i beskrivelsen, farmasøytisk akseptable salter, fremgangsmåter for fremstilling, farmasøytiske sammensetninger som inneholder dem og fremgangsmåter for anvendelse av samme.
NO20081862A 2005-09-21 2008-04-17 Alkylsulfoksidkinoliner som NK-3-reseptorligander NO20081862L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71928605P 2005-09-21 2005-09-21
US71927505P 2005-09-21 2005-09-21
PCT/SE2006/001068 WO2007035158A1 (en) 2005-09-21 2006-09-19 Alkyl sulfoxide quinolines as nk-3 receptor ligands

Publications (1)

Publication Number Publication Date
NO20081862L true NO20081862L (no) 2008-06-16

Family

ID=37889114

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081862A NO20081862L (no) 2005-09-21 2008-04-17 Alkylsulfoksidkinoliner som NK-3-reseptorligander

Country Status (17)

Country Link
US (1) US7964733B2 (no)
EP (1) EP1928835B1 (no)
JP (1) JP2009508946A (no)
KR (1) KR20080046669A (no)
AR (1) AR057130A1 (no)
AT (1) ATE506350T1 (no)
AU (1) AU2006292849A1 (no)
BR (1) BRPI0616136A2 (no)
CA (1) CA2621062A1 (no)
DE (1) DE602006021440D1 (no)
EC (1) ECSP088375A (no)
IL (1) IL189857A0 (no)
NO (1) NO20081862L (no)
RU (1) RU2008110914A (no)
TW (1) TW200800902A (no)
UY (1) UY29805A1 (no)
WO (1) WO2007035158A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234269A1 (en) * 2005-09-21 2008-09-25 Astrazeneca Ab N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands
KR20090122253A (ko) * 2007-03-19 2009-11-26 아스트라제네카 아베 퀴놀린 유도체, 이를 포함하는 제약 조성물, 및 중추신경계 및 말초 질환의 치료에서의 이의 용도
CA2680853C (en) * 2007-03-23 2012-07-17 Amgen Inc. 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69531458T2 (de) 1994-05-27 2004-08-05 Glaxosmithkline S.P.A. Chinolinderivate als tachykinin nk3 rezeptor antagonisten
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
GB9502644D0 (en) 1995-02-10 1995-03-29 Zeneca Ltd Heterocyclic derivatives
GB9513118D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
GB9524137D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
NZ323387A (en) 1995-11-24 2000-02-28 Smithkline Beecham Spa Quinoline derivatives having neurokinin antagonist activity, preparation and use thereof
BR9809652A (pt) 1997-05-23 2001-09-11 Smithkline Beecham Spa Derivados de quinolina-4-carboxamida como antagonistas de receptor nk-2 e nk-3
AP1201A (en) * 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
AU768708B2 (en) 1998-11-20 2004-01-08 Smithkline Beecham Laboratoires Pharmaceutiques Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
GB0027701D0 (en) 2000-11-13 2000-12-27 Smithkline Beecham Spa Novel compounds
AU2002221923A1 (en) 2000-11-28 2002-06-11 Glaxosmithkline S.P.A. Novel compounds
WO2002044165A1 (en) 2000-11-28 2002-06-06 Glaxosmithkline Spa Quinoline derivatives as nk-3 antagonists
GB0109122D0 (en) 2001-04-11 2001-05-30 Smithkline Beecham Spa Novel compounds
EP1385839B1 (en) 2001-04-11 2006-02-22 GlaxoSmithKline S.p.A. 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0425075D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425077D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425076D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
CA2613001A1 (en) 2005-06-23 2006-12-28 Astrazeneca Ab Quinoline 3 -sulfonate esters as nk3 receptor modulators
US20080234269A1 (en) * 2005-09-21 2008-09-25 Astrazeneca Ab N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands
AR058051A1 (es) * 2005-09-21 2008-01-23 Astrazeneca Ab Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
WO2007039123A2 (en) 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
WO2007044251A2 (en) 2005-09-30 2007-04-19 Smithkline Beecham Corporation Pharmaceutical compositions

Also Published As

Publication number Publication date
JP2009508946A (ja) 2009-03-05
AR057130A1 (es) 2007-11-14
US20080214605A1 (en) 2008-09-04
UY29805A1 (es) 2007-04-30
US7964733B2 (en) 2011-06-21
TW200800902A (en) 2008-01-01
KR20080046669A (ko) 2008-05-27
DE602006021440D1 (de) 2011-06-01
BRPI0616136A2 (pt) 2011-06-07
AU2006292849A1 (en) 2007-03-29
WO2007035158A1 (en) 2007-03-29
RU2008110914A (ru) 2009-10-27
ATE506350T1 (de) 2011-05-15
EP1928835B1 (en) 2011-04-20
EP1928835A1 (en) 2008-06-11
ECSP088375A (es) 2008-05-30
CA2621062A1 (en) 2007-03-29
IL189857A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
NO20083434L (no) Benzamid- og heteroarenderivater
NO20084915L (no) Nikotinacetylcholinreseptorligander 101
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
NO20084129L (no) Pyridin(3,4-B)Pyrazinoner
WO2005123731A3 (en) Pyrrolopyridine derivatives and their use as crth2 antagonists
NO20092314L (no) Benzamidderivater som EP4 receptoragonister
NO20073551L (no) Nikotinacetylkolinreseptorligander
NO20066055L (no) Pyridinderivater
MXPA05011597A (es) Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina.
NO20081217L (no) Nye benzotiazolonderivater
NO20071504L (no) Pyrimidinderivanter.
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
MY186650A (en) Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
NO20092689L (no) Quinuclidinolderivater som muskarin reseptorantagonister
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
NO20080033L (no) Kinolinderivater som NK3-antagonister
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
NZ552137A (en) New 4-benzylidene-piperidin derivatives
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
GEP20104964B (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application